Gene polymorphism affecting alpha1-antichymotrypsin and interleukin-1 plasma levels increases Alzheimer's disease risk

Ann Neurol. 2000 Sep;48(3):388-91.


Plasma levels of alpha1-antichymotrypsin (ACT) and interleukin-1beta (IL-1beta) were increased in patients with probable Alzheimer's disease (AD). A common polymorphism within ACT and IL-1beta genes affected plasma levels of ACT or IL-1beta, and AD patients with the ACT T,T or IL-1beta T,T genotype showed the highest levels of plasma ACT or IL-1beta, respectively. The concomitant presence of the ACT T,T and IL-1beta T,T genotypes increased the risk of AD (odds ratio: 5.606, confidence interval: 1.654-18.996) and decreased the age at onset of the disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Alzheimer Disease / blood*
  • Alzheimer Disease / genetics*
  • Analysis of Variance
  • Genotype
  • Humans
  • Interleukin-1 / blood*
  • Interleukin-1 / genetics*
  • Polymorphism, Genetic / genetics*
  • Risk Factors
  • alpha 1-Antichymotrypsin / blood*
  • alpha 1-Antichymotrypsin / genetics*


  • Interleukin-1
  • alpha 1-Antichymotrypsin